Pipeline dossier

NIH & clinical-trial pipeline signals for Immunome Inc. (IMNM)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for IMNM, mapped to public ticker IMNM (CIK 0001472012). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingIMNM35% conf

Immunome Inc. (IMNM) — EARLY_PHASE1 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (EARLY_PHASE1) — A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Recent SEC 8-K filings

2026-06-12 — 8-K 5.07 view ↗
2026-05-12 — 8-K 2.02,9.01 view ↗
2026-03-03 — 8-K 2.02,9.01 view ↗
2025-12-17 — 8-K 8.01,9.01 view ↗
2025-12-15 — 8-K 7.01,8.01,9.01 view ↗

JSON API for this entity →